Search - tctmd.com

Displaying 561 - 575 of 575

Sort: Relevancy | Date

News Daily News

More Than Half of CVD Studies Exclude Patients With Kidney Disease

Michael O'Riordan

December 03, 2015

Presentation

Representation of Patients With Kidney Disease in Trials of CVD Interventions

Presenter: Ioannis Konstantinidis

December 02, 2015

News Conference News AHA 2015

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

Shelley Wood

November 05, 2015

News Daily News

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Caitlin E. Cox

October 27, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

August 31, 2015

News Industry News

Navidea and Massachusetts General Hospital to Evaluate Manocept™ for Detection of Cardiovascular Disease with NIH Grant

July 28, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

June 22, 2015

News Industry News

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

June 09, 2015

News Daily News

Improved Homing of Cardiac Stem Cells Shows Promise for Cardiomyopathy

February 21, 2013

News Daily News

El Tropismo Mejorado de las Células Madre Cardíacas contra la Cardiomiopatía resulta Prometedor

February 21, 2013

News Daily News

High Homocysteine Levels Linked with Contrast Nephropathy

Jason Kahn

July 28, 2011

News Daily News

CUPID: Gene Therapy Holds Promise in Heart Failure

July 12, 2011

CME

Advertisement

More Than Half of CVD Studies Exclude Patients With Kidney Disease

Representation of Patients With Kidney Disease in Trials of CVD Interventions

AHA 2015 Promises Appropriate PCI, Ticagrelor Tolerance, Outcomes With IVUS, and More

No Money, No Drugs: Global Barriers to Secondary CVD Prevention

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor

Navidea and Massachusetts General Hospital to Evaluate Manocept™ for Detection of Cardiovascular Disease with NIH Grant

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

First CVD Outcome Trial of a GLP-1 Agonist Finds No Cardiac Risk or Benefit

Improved Homing of Cardiac Stem Cells Shows Promise for Cardiomyopathy

El Tropismo Mejorado de las Células Madre Cardíacas contra la Cardiomiopatía resulta Prometedor

High Homocysteine Levels Linked with Contrast Nephropathy

CUPID: Gene Therapy Holds Promise in Heart Failure

Role of Interventional Cardiologists in Secondary Prevention of Acute Coronary Syndromes: Redefining Clinical Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content